Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.
Identifieur interne : 001643 ( PubMed/Corpus ); précédent : 001642; suivant : 001644Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.
Auteurs : I. Mendez ; A. Dagher ; M. Hong ; A. Hebb ; P. Gaudet ; A. Law ; S. Weerasinghe ; D. King ; J. Desrosiers ; S. Darvesh ; T. Acorn ; H. RobertsonSource :
- Journal of neurosurgery [ 0022-3085 ] ; 2000.
English descriptors
- KwdEn :
- Aged, Brain Tissue Transplantation (pathology), Cell Count, Cell Line, Cell Survival, Dihydroxyphenylalanine (analogs & derivatives), Dopamine (secretion), Feasibility Studies, Fetal Tissue Transplantation (pathology), Fluorine Radioisotopes, Follow-Up Studies, Graft Survival, Humans, Male, Mesencephalon (cytology), Mesencephalon (drug effects), Mesencephalon (embryology), Middle Aged, Nerve Growth Factor (therapeutic use), Neuroglia, Parkinson Disease (surgery), Putamen (surgery), Radiopharmaceuticals, Substantia Nigra (cytology), Substantia Nigra (drug effects), Substantia Nigra (embryology), Substantia Nigra (transplantation), Tissue Preservation, Tomography, Emission-Computed, Treatment Outcome, Tyrosine 3-Monooxygenase (analysis).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , analysis : Tyrosine 3-Monooxygenase.
- cytology : Mesencephalon, Substantia Nigra.
- drug effects : Mesencephalon, Substantia Nigra.
- embryology : Mesencephalon, Substantia Nigra.
- pathology : Brain Tissue Transplantation, Fetal Tissue Transplantation.
- chemical , secretion : Dopamine.
- surgery : Parkinson Disease, Putamen.
- chemical , therapeutic use : Nerve Growth Factor.
- transplantation : Substantia Nigra.
- Aged, Cell Count, Cell Line, Cell Survival, Feasibility Studies, Fluorine Radioisotopes, Follow-Up Studies, Graft Survival, Humans, Male, Middle Aged, Neuroglia, Radiopharmaceuticals, Tissue Preservation, Tomography, Emission-Computed, Treatment Outcome.
Abstract
The authors have studied the ability of glial cell line-derived neurotrophic factor (GDNF) to promote survival of human fetal dopaminergic tissue after a storage period of 6 days and subsequent implantation into the human putamen. The results indicate that GDNF promotes survival of stored dopaminergic cells. Cells stored without GDNF had a 30.1% decrease in survival time compared with those exposed to GDNF. Two patients with Parkinson's disease received bilateral putaminal implants of fetal dopaminergic cells exposed to GDNF for 6 days and showed enhancement of graft survival as assessed by positron emission tomography scanning. A mean increase of 107% in putaminal fluorodopa uptake from baseline values was observed 12 months postgrafting.
DOI: 10.3171/jns.2000.92.5.0863
PubMed: 10794303
Links to Exploration step
pubmed:10794303Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.</title><author><name sortKey="Mendez, I" sort="Mendez, I" uniqKey="Mendez I" first="I" last="Mendez">I. Mendez</name><affiliation><nlm:affiliation>Department of Surgery, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. mendez@is.dal.ca</nlm:affiliation></affiliation></author><author><name sortKey="Dagher, A" sort="Dagher, A" uniqKey="Dagher A" first="A" last="Dagher">A. Dagher</name></author><author><name sortKey="Hong, M" sort="Hong, M" uniqKey="Hong M" first="M" last="Hong">M. Hong</name></author><author><name sortKey="Hebb, A" sort="Hebb, A" uniqKey="Hebb A" first="A" last="Hebb">A. Hebb</name></author><author><name sortKey="Gaudet, P" sort="Gaudet, P" uniqKey="Gaudet P" first="P" last="Gaudet">P. Gaudet</name></author><author><name sortKey="Law, A" sort="Law, A" uniqKey="Law A" first="A" last="Law">A. Law</name></author><author><name sortKey="Weerasinghe, S" sort="Weerasinghe, S" uniqKey="Weerasinghe S" first="S" last="Weerasinghe">S. Weerasinghe</name></author><author><name sortKey="King, D" sort="King, D" uniqKey="King D" first="D" last="King">D. King</name></author><author><name sortKey="Desrosiers, J" sort="Desrosiers, J" uniqKey="Desrosiers J" first="J" last="Desrosiers">J. Desrosiers</name></author><author><name sortKey="Darvesh, S" sort="Darvesh, S" uniqKey="Darvesh S" first="S" last="Darvesh">S. Darvesh</name></author><author><name sortKey="Acorn, T" sort="Acorn, T" uniqKey="Acorn T" first="T" last="Acorn">T. Acorn</name></author><author><name sortKey="Robertson, H" sort="Robertson, H" uniqKey="Robertson H" first="H" last="Robertson">H. Robertson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10794303</idno><idno type="pmid">10794303</idno><idno type="doi">10.3171/jns.2000.92.5.0863</idno><idno type="wicri:Area/PubMed/Corpus">001643</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001643</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.</title><author><name sortKey="Mendez, I" sort="Mendez, I" uniqKey="Mendez I" first="I" last="Mendez">I. Mendez</name><affiliation><nlm:affiliation>Department of Surgery, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. mendez@is.dal.ca</nlm:affiliation></affiliation></author><author><name sortKey="Dagher, A" sort="Dagher, A" uniqKey="Dagher A" first="A" last="Dagher">A. Dagher</name></author><author><name sortKey="Hong, M" sort="Hong, M" uniqKey="Hong M" first="M" last="Hong">M. Hong</name></author><author><name sortKey="Hebb, A" sort="Hebb, A" uniqKey="Hebb A" first="A" last="Hebb">A. Hebb</name></author><author><name sortKey="Gaudet, P" sort="Gaudet, P" uniqKey="Gaudet P" first="P" last="Gaudet">P. Gaudet</name></author><author><name sortKey="Law, A" sort="Law, A" uniqKey="Law A" first="A" last="Law">A. Law</name></author><author><name sortKey="Weerasinghe, S" sort="Weerasinghe, S" uniqKey="Weerasinghe S" first="S" last="Weerasinghe">S. Weerasinghe</name></author><author><name sortKey="King, D" sort="King, D" uniqKey="King D" first="D" last="King">D. King</name></author><author><name sortKey="Desrosiers, J" sort="Desrosiers, J" uniqKey="Desrosiers J" first="J" last="Desrosiers">J. Desrosiers</name></author><author><name sortKey="Darvesh, S" sort="Darvesh, S" uniqKey="Darvesh S" first="S" last="Darvesh">S. Darvesh</name></author><author><name sortKey="Acorn, T" sort="Acorn, T" uniqKey="Acorn T" first="T" last="Acorn">T. Acorn</name></author><author><name sortKey="Robertson, H" sort="Robertson, H" uniqKey="Robertson H" first="H" last="Robertson">H. Robertson</name></author></analytic><series><title level="j">Journal of neurosurgery</title><idno type="ISSN">0022-3085</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Brain Tissue Transplantation (pathology)</term><term>Cell Count</term><term>Cell Line</term><term>Cell Survival</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dopamine (secretion)</term><term>Feasibility Studies</term><term>Fetal Tissue Transplantation (pathology)</term><term>Fluorine Radioisotopes</term><term>Follow-Up Studies</term><term>Graft Survival</term><term>Humans</term><term>Male</term><term>Mesencephalon (cytology)</term><term>Mesencephalon (drug effects)</term><term>Mesencephalon (embryology)</term><term>Middle Aged</term><term>Nerve Growth Factor (therapeutic use)</term><term>Neuroglia</term><term>Parkinson Disease (surgery)</term><term>Putamen (surgery)</term><term>Radiopharmaceuticals</term><term>Substantia Nigra (cytology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (embryology)</term><term>Substantia Nigra (transplantation)</term><term>Tissue Preservation</term><term>Tomography, Emission-Computed</term><term>Treatment Outcome</term><term>Tyrosine 3-Monooxygenase (analysis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Mesencephalon</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Mesencephalon</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="embryology" xml:lang="en"><term>Mesencephalon</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain Tissue Transplantation</term><term>Fetal Tissue Transplantation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="secretion" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nerve Growth Factor</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cell Count</term><term>Cell Line</term><term>Cell Survival</term><term>Feasibility Studies</term><term>Fluorine Radioisotopes</term><term>Follow-Up Studies</term><term>Graft Survival</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroglia</term><term>Radiopharmaceuticals</term><term>Tissue Preservation</term><term>Tomography, Emission-Computed</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The authors have studied the ability of glial cell line-derived neurotrophic factor (GDNF) to promote survival of human fetal dopaminergic tissue after a storage period of 6 days and subsequent implantation into the human putamen. The results indicate that GDNF promotes survival of stored dopaminergic cells. Cells stored without GDNF had a 30.1% decrease in survival time compared with those exposed to GDNF. Two patients with Parkinson's disease received bilateral putaminal implants of fetal dopaminergic cells exposed to GDNF for 6 days and showed enhancement of graft survival as assessed by positron emission tomography scanning. A mean increase of 107% in putaminal fluorodopa uptake from baseline values was observed 12 months postgrafting.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10794303</PMID><DateCreated><Year>2000</Year><Month>05</Month><Day>17</Day></DateCreated><DateCompleted><Year>2000</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3085</ISSN><JournalIssue CitedMedium="Print"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurosurgery</Title><ISOAbbreviation>J. Neurosurg.</ISOAbbreviation></Journal><ArticleTitle>Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.</ArticleTitle><Pagination><MedlinePgn>863-9</MedlinePgn></Pagination><Abstract><AbstractText>The authors have studied the ability of glial cell line-derived neurotrophic factor (GDNF) to promote survival of human fetal dopaminergic tissue after a storage period of 6 days and subsequent implantation into the human putamen. The results indicate that GDNF promotes survival of stored dopaminergic cells. Cells stored without GDNF had a 30.1% decrease in survival time compared with those exposed to GDNF. Two patients with Parkinson's disease received bilateral putaminal implants of fetal dopaminergic cells exposed to GDNF for 6 days and showed enhancement of graft survival as assessed by positron emission tomography scanning. A mean increase of 107% in putaminal fluorodopa uptake from baseline values was observed 12 months postgrafting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. mendez@is.dal.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagher</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hebb</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gaudet</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Weerasinghe</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Desrosiers</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Darvesh</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Acorn</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosurg</MedlineTA><NlmUniqueID>0253357</NlmUniqueID><ISSNLinking>0022-3085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>2C598205QX</RegistryNumber><NameOfSubstance UI="C043437">fluorodopa F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9061-61-4</RegistryNumber><NameOfSubstance UI="D020932">Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016380" MajorTopicYN="Y">Brain Tissue Transplantation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004295" MajorTopicYN="N">Dihydroxyphenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000557" MajorTopicYN="N">secretion</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="Y">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006085" MajorTopicYN="Y">Graft Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020932" MajorTopicYN="N">Nerve Growth Factor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014021" MajorTopicYN="N">Tissue Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10794303</ArticleId><ArticleId IdType="doi">10.3171/jns.2000.92.5.0863</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001643 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001643 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10794303
|texte= Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10794303" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |